The Pathophysiology of Secondary Hyperparathyroidism and the Consequences of Uncontrolled Mineral Metabolism in Chronic Kidney Disease: The Role of COSMOS
Open Access
- 1 January 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 1 (suppl 1) , i2-i6
Abstract
The development of secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease. SHPT develops as a consequence of mineral metabolism disturbances and is characterized by elevated serum parathyroid hormone (PTH) and parathyroid hyperplasia. Evidence suggests that SHPT contributes to the development of vascular calcification and cardiovascular disease, as well as to the development of renal osteodystrophy. The elevated serum calcium, phosphorus, calcium–phosphorus product and PTH that accompany SHPT have been independently associated with an increased relative risk of mortality. Despite the danger that these risks represent, achieving control of mineral metabolism in SHPT is difficult. Recent evidence from the Current Management of Secondary Hyperparathyroidism: Multicentre Observational Study has shown that fewer than 1 in 10 haemodialysis patients simultaneously meet their National Kidney Foundation Kidney Disease Outcomes Quality Initiative targets for serum calcium, phosphorus, calcium–phosphorus product and PTH with standard treatments. There is therefore an urgent need for new strategies and novel pharmacologic therapies that improve control of mineral metabolism and PTH secretion in SHPT and thus reduce the mortality associated with this condition.Keywords
This publication has 45 references indexed in Scilit:
- Medical therapy of secondary hyperparathyroidism in chronic kidney disease: old and new drugsExpert Opinion on Pharmacotherapy, 2006
- Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns StudyKidney International, 2005
- Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)American Journal of Kidney Diseases, 2004
- Mineral Metabolism, Mortality, and Morbidity in Maintenance HemodialysisJournal of the American Society of Nephrology, 2004
- Pathogenesis of refractory secondary hyperparathyroidismKidney International, 2002
- A Conserved cis-Acting Element in the Parathyroid Hormone 3′-Untranslated Region Is Sufficient for Regulation of RNA Stability by Calcium and PhosphateJournal of Biological Chemistry, 2001
- Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patientsAmerican Journal of Kidney Diseases, 1996
- Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D.Journal of Clinical Investigation, 1995
- Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat.Journal of Clinical Investigation, 1990
- The metabolism and mechanism of action of 1,25-dihydroxyvitamin D3Kidney International, 1986